PIVOTAL has been awarded by ADEFAM the Special Mention Award for the Most innovative Business Project of the Year 2025

PIVOTAL has been awarded by ADEFAM the Special Mention Award for the Most innovative Business Project of the Year 2025

•     Dr. Ibrahim Farr, Chairman & CEO, and Lidia Farr, Senior VP Corporate Development & Finance of Pivotal, collected the award for innovation during the annual ceremony
•     Danah® AI & Analytics, the award-winning platform, was also recognized by the CDTI (Center for Technological Development and Innovation) and is co-financed by the European Regional Development Fund (ERDF) with the aim of promoting technological development, innovation and quality research

Madrid, Spain, April 8, 2025 – ADEFAM, the Family Business Association of Madrid, recently held the seventh edition of its annual awards ceremony on the 31st March 2025.

On this occasion, PIVOTAL, a European CRO (Contract Clinical Research Organization) with global presence and dedicated to cutting-edge clinical research into new drugs in various therapeutic areas, was awarded the prize for the most innovative business project. “It has been years of hard work and perseverance, so we are very excited about this recognition from ADEFAM,” said Lidia Farr.

Danah® AI & Analytics is an advanced platform that eliminates silos in the management of data generated in clinical trials, presents it in real time and uses Artificial Intelligence to identify and predict clinical risks in patients, anticipating decision making and increasing the safety of patients participating in clinical trials. “This project would not have been possible without the dedication and effort of the Danah® team, who have created a cutting-edge platform that is changing the way clinical trials are managed. We will continue to invest heavily in innovation as before, because innovation is not the destination, it is the way forward,” said Lidia Farr.

About Pivotal
Pivotal was born and raised in 2001 surrounded by an environment of high scientific tenure and drive. Our founder, Dr. Ibrahim Farr, launched Pivotal to share and implement scientific strategies and best project practices that make clinical trials more efficient and maximize our client’s drug development programs’ value chain. As a company with some 200 employees and operating in more than 20 countries we have built focused specialization across all therapeutic areas and founded a strong innovative therapies and early phases hub that enables us to tackle our customers most difficult challenges. After almost a quarter of a century of hands-on experience, we master clinical research.

Pivotal has forged an aspirational vision of a digitally and data-enabled, growth-oriented future. We dive deep into clinical trials by leveraging our near real time advanced insights platform. We discover data-driven insights to anticipate trial risks and predict their impact. This has made us an efficient, agile and resilient company, very focused on our customers. We are a technology-savvy organization.

For more information, please visit www.pivotalcr.com and follow us on LinkedIn

MEDIA CONTACT
Natalia Farr, MA Journalism
Sr Manager, Communications & Training
Email: Natalia.Farr@pivotalcr.com
Telephone: +34 679 488 022